American media and the welltuned brain, which is the book that dr. Peter whybrow will be talking about this evening. Welcome, dr. Whybrow. Thank you so much for coming to speak with us this evening. This is a real treat for so many of us. We even have people here from oxford, from france, and we are just delighted to welcome you this evening. Joining dr. Whybrow in discussion will be another preeminent scientist from the institute, dr. Andrew loopter who is a professor of psychiatry and Biobehavioral Sciences and the director of the Neuromodulation Center at the Semel Institute. Hes also our faculty adviser. So we would like to thank dr. Luketer also for being here this evening and for sharing his knowledge and expertise with us. A few housekeeping items. After the presentation we will have a discussion. You will receive if you would like to ask a question, please pick up an index card that will be passed around by some of our board members, write your question on the index card, and s
Woodcock set to retire from FDA in early 2024—Chutes & Ladders
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
Mural Oncology Launches To Advance Pipeline Of Novel Engineered Cytokine Immunotherapies
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Mural Oncology plc spins out from Alkermes plc with $275 million in committed funding, providing a cash runway projected into 4Q 2025 Company’s lead product candidate – nemvaleukin alfa – being developed to treat a wide range of solid tumors – is currently in two potentially registrational clinical trials, both with readouts expected in 1Q 2025 Mural is also advancing engineered therapies targeting interleukin-18 and interleukin-12 with plans to nominate a development candidate for each program